Substituted Biaryl Compounds for Selective Factor XIa Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serine protease inhibitors for factor XIa and plasma kallikrein lack selectivity and efficacy, particularly in preventing thromboembolic disorders and inflammation, with limitations in pharmacological characteristics such as oral bioavailability, dosage requirements, and potential adverse side effects.
Innovation Solution
Development of novel substituted biaryl compounds that act as selective inhibitors of serine protease enzymes, specifically factor XIa and plasma kallikrein, with improved inhibitory activity and selectivity, formulated into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current serine protease inhibitors are used for factor XIa and plasma kallikrein, then inhibition activity is achieved, but selectivity and efficacy are insufficient leading to adverse side effects
Solution Approach 1:
The patent applies local quality by designing specific substitution patterns on the biaryl core structure. Different substituents (R1-R6) are placed at specific positions to create localized interactions with the factor XIa active site, enhancing selectivity while minimizing off-target effects on other serine proteases
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types, positions, and stereochemistry of the biaryl compounds. This optimization of molecular parameters achieves enhanced inhibitory activity and selectivity for factor XIa over other proteases
2Reliability
If current inhibitors are used, then some therapeutic effect is achieved, but oral bioavailability and pharmacological characteristics are limited
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by modifying molecular weight, lipophilicity, and hydrogen bonding capacity through strategic substituent selection. These parameter changes improve oral bioavailability while maintaining therapeutic efficacy
3Reliability
If selective factor XIa inhibitors are developed, then antithrombotic and anti-inflammatory effects are enhanced, but manufacturing complexity may increase
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional modules: a core biaryl structure, substituent groups at specific positions, and stereocenters. This modular approach enables systematic optimization of efficacy while simplifying manufacturing through standardized synthesis pathways for each module
Data Source
AI summary
The present invention provides compounds of Formula (I):or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, and ring B are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.